Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
- Conditions
- Refractory Marginal Zone LymphomaRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaRecurrent Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRecurrent Waldenstrom Macroglobulinemia
- Interventions
- Drug: BortezomibDrug: DexamethasoneOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentBiological: RituximabDrug: Temsirolimus
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01381692
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years
- Conditions
- Acute Lymphoblastic Leukemia Ph Positive
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT01376427
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 413
- Registration Number
- NCT01376297
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States
🇺🇸East Valley Hematology and Oncology Medical Group, Burbank, California, United States
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 14
- Registration Number
- NCT01374217
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Meir Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01372904
- Locations
- 🇮🇱
Clalit Health Services, Haifa, Israel
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsRecurrent Burkitt LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeBurkitt-Like Lymphoma With 11q AberrationRecurrent B Acute Lymphoblastic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedRefractory B Acute Lymphoblastic LeukemiaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biological: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneBiological: Inotuzumab OzogamicinDrug: MethotrexateOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: PrednisoneBiological: RituximabDrug: Vincristine
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 276
- Registration Number
- NCT01371630
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01370408
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- Precursor T-Cell Lymphoblastic LymphomaLymphoblastic Leukemia, Acute T-cell
- Interventions
- Drug: BMS-906024Drug: Dexamethasone
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 31
- Registration Number
- NCT01363817
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 743
- Registration Number
- NCT01363479
- Locations
- 🇺🇸
Facey Medical Group, Mission Hills, California, United States
🇺🇸Northern Utah Associates [Hematology/ Oncology], Ogden, Utah, United States
🇺🇸Genesis Cancer Centre, Hot Springs, Arkansas, United States
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Adult Acute Lymphoblastic Leukemia in Complete RemissionBurkitt LeukemiaBurkitt LymphomaChildhood Acute Lymphoblastic Leukemia in Complete RemissionAcute Lymphoblastic LeukemiaCD20 PositiveLymphoblastic Lymphoma
- Interventions
- Drug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MethotrexateBiological: OfatumumabDrug: Vincristine Sulfate
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT01363128
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.